Analysts Offer Insights on Healthcare Companies: Aethlon Medical (AEMD), Humana (HUM) and Palvella Therapeutics (PVLA)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Aethlon Medical (AEMD – Research Report), Humana (HUM – Research Report) and Palvella Therapeutics (PVLA – Research Report).
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Aethlon Medical (AEMD)
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Hold rating on Aethlon Medical today and set a price target of $1.50. The company’s shares closed last Friday at $1.96.
According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of
Aethlon Medical has an analyst consensus of Hold, with a price target consensus of $2.05, which is a 4.6% upside from current levels. In a report issued on February 2, TipRanks – xAI also upgraded the stock to Hold with a $2.50 price target.
See today’s best-performing stocks on TipRanks >>
Humana (HUM)
In a report released today, A.J. Rice from UBS maintained a Hold rating on Humana, with a price target of $195.00. The company’s shares closed last Friday at $184.10.
According to TipRanks.com, Rice is a 5-star analyst with an average return of
Humana has an analyst consensus of Hold, with a price target consensus of $225.29, which is a 26.0% upside from current levels. In a report issued on February 12, RBC Capital also downgraded the stock to Hold with a $189.00 price target.
Palvella Therapeutics (PVLA)
Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Palvella Therapeutics today and set a price target of $205.00. The company’s shares closed last Friday at $81.54.
According to TipRanks.com, Suvannavejh is a 5-star analyst with an average return of
Currently, the analyst consensus on Palvella Therapeutics is a Strong Buy with an average price target of $179.42, which is an 119.4% upside from current levels. In a report issued on February 2, TD Cowen also maintained a Buy rating on the stock with a $190.00 price target.
